)
Edge14 Aug 2026
Deutsche Qualität: The Story of Birkenstock
From an 18th-century German shoemaker to a global footwear brand, how Birkenstock turned an orthopedic insole into the world's most popular sandal.
Nuvectis Pharma
Nuvectis Pharma (NVCT) investor relations material
Nuvectis Pharma Corporate presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate presentation summary10 Aug, 2026
Management and strategic partnerships
Leadership team has a track record of securing global regulatory approvals in renal, anemia, and oncology indications.
Entered a transformative licensing agreement with Haisco Pharmaceutical Group, a partner with extensive marketed products and research programs.
Haisco has a history of successful licensing deals and drug development, including positive Phase 3 data for a TYK2 inhibitor.
Financial highlights and capital position
Completed a $115M follow-on offering in July 2026.
Cash runway extends into the first half of 2029, supporting broad clinical plans.
Positioned to reach key inflection points with multiple near-term clinical and regulatory catalysts expected.
Pipeline overview and clinical progress
Ciprocopan (NXP100): Once-daily, oral Factor B inhibitor for complement-related diseases, approved in China for treatment-naïve PNH, with additional indications in late-stage studies.
NXP200: Oral, brain-penetrant, paradox-breaker BRAF inhibitor in Phase 1b for solid tumors and CNS cancers, showing durable single-agent responses.
NXP900: SRC/YES1 kinase inhibitor in Phase 1b combination studies for NSCLC and planned studies in pancreatic cancer.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Nuvectis Pharma
- Q2 2026 net loss was $7.0M; $115M raised in July extends cash runway into 1H 2029.NVCT
Q2 2026 - Late-stage NXP100 and NXP200 in-licensed, expanding pipeline in complement and oncology.NVCTStatus update
- Director election and auditor ratification approved; full results to be filed with SEC.NVCTAGM 2026
- NXP900 demonstrates potent, selective SRC inhibition and promising safety in early clinical trials.NVCTH.C. Wainwright 4th Annual BioConnect Investor Conference
- NXP900 shows promise in overcoming resistance in solid tumors and NSCLC with strong early data.NVCTCorporate presentation
- Q1 2026 net loss was $6.1M as NXP900 clinical progress drove higher R&D and G&A costs.NVCTQ1 2026
- Vote on director election and auditor ratification at the June 2026 annual meeting.NVCTProxy filing
- Annual meeting to vote on director election and auditor ratification, with strong governance.NVCTProxy filing
- NXP900’s oral regimen targets resistance and unmet needs in NSCLC with a novel, well-tolerated approach.NVCTKOL Event
Next Nuvectis Pharma earnings date
Q3 20265 Nov, 2026
Nuvectis Pharma
Next Nuvectis Pharma earnings date
Q3 20265 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage